TY  - JOUR
T1  - TElaprevir warning
AU  - Kuehn BM
Y1  - 2013/01/23
N1  - 10.1001/jama.2013.22
JO  - JAMA
SP  - 333
EP  - 333
VL  - 309
IS  - 4
N2  - 
The label for telaprevir already warns about the potential for serious skin reactions such as Stevens-Johnson syndrome and drug rash with eosinophilia and systemic symptoms (DRESS). But the FDA has now received 2 reports from Japan of toxic epidermal necrolysis in patients taking telaprevir combination therapy. One of the patients died after therapy was continued despite signs of a skin reaction. The FDA has also received a report of a woman who had developed DRESS and died after telaprevir combination treatment was continued.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2013.22
UR  - http://dx.doi.org/10.1001/jama.2013.22
ER  -